Search Results for: FORMULATION DEVELOPMENT TECHNOLOGY A Novel
Articles
Rexahn Pharmaceuticals Receives New US Patent
Rexahn Pharmaceuticals, Inc. recently announced that the United States Patent and Trademark Office has issued US Patent No. 9,744,167, Nanoparticulate...Enteris Biopharma Doses First Woman in Phase 2a Clinical Trial
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, recently announced the first...Aptevo Therapeutics Highlights ADAPTIR™ Protein Therapeutic Platform
Aptevo Therapeutics Inc. recently announced that aspects of its ADAPTIR protein therapeutic platform were showcased recently at the Americas Antibody...SPECIAL FEATURE - Wanted: New Excipients to Meet the Demands of a Challenging Industry
Contributor Cindy H. Dubin recently spoke with some of the leading excipient innovators to find out what types of excipients they are developing, the advantages they offer to formulations, and where they see the industry focusing throughout the next few years.
EXECUTIVE INTERVIEW - Oasmia Pharmaceutical: Commercializing Technologies While Pursuing the US Market
Julian Aleksov, Executive Chairman of Oasmia Pharmaceutical, discusses his company’s efforts to enter the US market, its strategy to increase commercial adoption, and why it believes its underlying drug delivery system technology is significant not only within the oncology sector, but the entire pharmaceutical industry.
GNT Biotech & Medicals Corporation to Begin Phase III Clinical Trial
GNT Biotech & Medicals Co., Ltd. recently announced that the anticancer drug Chidamide (HBI-8000), an epigenetic regulator developed by Chipscreen...UroGen Pharma Announces Enrollment of First Patient in Phase III Clinical Trial
UroGen Pharma Ltd. recently announced the first patient has been enrolled in the OLYMPUS trial, an open-label, single-arm pivotal Phase...ANTIMICROBIAL RESISTANCE - MGB: The Minor Groove Binder
Dawn A. Firmin, MSc, PhD, explains how MGB has dedicated its focus to the development of a new class of small molecules, with specific antibacterial activity against susceptible and resistant bacteria.
ANTIMICROBIAL LIPIDS - Attenuating the Use of Medically Important Antimicrobial Drugs in Food-Producing Animals: What Role Can cGMP Lipids Play?
Ryan Littich, PhD, highlights some of the most significant, pathogen-borne diseases relevant to food-producing animals and reviews the antimicrobial properties intrinsic to midchain triglyceride lipolysis products.
Aclaris Therapeutics Submits NDA for Seborrheic Keratosis
Aclaris Therapeutics, Inc. recently announced it has submitted a New Drug Application (NDA) to the US FDA for A-101 40%...
